Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Date publication

août 2017

Journal

Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse

Tous les auteurs :
Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28387928

Résumé

Sorafenib has shown encouraging results in patients with Fms-like tyrosine kinase 3 (FLT3)-positive acute myeloid leukemia. Its role after allogeneic stem cell transplantation (HSCT) has been reported in a few cases with encouraging results.

Mots clés

Adolescent, Adult, Antineoplastic Agents, therapeutic use, Chemotherapy, Adjuvant, Disease-Free Survival, Feasibility Studies, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, drug therapy, Maintenance Chemotherapy, Male, Middle Aged, Niacinamide, analogs & derivatives, Phenylurea Compounds, therapeutic use, Retrospective Studies, Transplantation, Homologous, Treatment Outcome, Young Adult, fms-Like Tyrosine Kinase 3, genetics

Référence

Cancer. 2017 Aug 1;123(15):2867-2874